Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABBV-992
- Development stage
- Phase 1
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ABBV-992 is an orally bioavailable, irreversible covalent inhibitor of Bruton's tyrosine kinase (BTK), developed by AbbVie for the treatment of B-cell malignancies. By binding to and inhibiting BTK, ABBV-992 blocks activation of the B-cell antigen receptor signaling pathway, which is critical for the survival and proliferation of malignant B cells. The drug has demonstrated potency and selectivity as a BTK inhibitor and was advanced to Phase I clinical trials primarily targeting cancers such as chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and other B-cell cancers[1][3][4][8].
02
Targets
BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on ABBV-992.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABBV-992.